<DOC>
	<DOCNO>NCT00000778</DOCNO>
	<brief_summary>To evaluate methodology rapidly determine early bactericidal activity ( EBA ) , tolerance , pharmacokinetics isoniazid levofloxacin treatment pulmonary tuberculosis ( TB ) . Traditionally , trial treatment TB , new drug administer combination two antituberculous agent know effectiveness long period time . In set , difficult determine effect single drug dose level . Development new agent treatment TB may accelerate methodology new agent could evaluate activity administer single agent short time period . This study utilize method measure amount bacteria present day lung .</brief_summary>
	<brief_title>A Pilot Study Methodology Rapidly Evaluate Drugs Bactericidal Activity , Tolerance , Pharmacokinetics Treatment Pulmonary Tuberculosis Using Isoniazid Levofloxacin</brief_title>
	<detailed_description>Traditionally , trial treatment TB , new drug administer combination two antituberculous agent know effectiveness long period time . In set , difficult determine effect single drug dose level . Development new agent treatment TB may accelerate methodology new agent could evaluate activity administer single agent short time period . This study utilize method measure amount bacteria present day lung . An initial cohort patient receive isoniazid ( pyridoxine ) daily 5 day . Sputum sample collect daily determination EBA ( decline colony-forming units/ml sputum ) . If methodology validate , additional patient randomize receive one two dos levofloxacin daily 5 day , determination EBA . All patient hospitalize 2 day baseline evaluation 5 day treatment .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed patient : Antacids administer 2 hour study drug . Allowed isoniazid patient : Anticonvulsant therapy blood level monitor . Allowed levofloxacin patient : Acceptable medication antacid administer least 2 hour 1 hour study drug . Anticonvulsant therapy , theophylline , warfarin dos monitor . Patients must : Presumptive active pulmonary TB . No clinical evidence central nervous system miliary tuberculosis . NOTE : Both HIVpositive HIVnegative patient eligible . NOTE : Pregnant woman may enrol isoniazid cohort . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active suspect MAI infection . Active suspect hepatitis . Any serious acute infection , diabetes , chronic obstructive pulmonary disease , malignancy require chemotherapy , major organ dysfunction . Extreme illness toxic appearance . Pregnancy ( enter levofloxacin portion study ) . Concurrent Medication : Excluded : All standard TB therapy . Clofazimine . Rifabutin . Quinolones . Aminoglycosides . Corticosteroids . Pentoxifylline . Colonystimulating factor . Interferons . Interleukins . Disulfiram ( patient receive isoniazid ) . Patients follow prior condition exclude : History treatmentlimiting intolerance know hypersensitivity isoniazid ( patient receive isoniazid ) quinolones ( patient receive levofloxacin ) . Vomiting diarrhea &gt; = grade 2 screen within 2 day prior screen . History drugresistant TB ( patient receive isoniazid ) . Prior Medication : Excluded : Any prior treatment prophylaxis TB enrol isoniazid cohort . Any antiTB drug within past 12 week , include standard drug TB well clofazimine , rifabutin , quinolones aminoglycosides . Corticosteroids , pentoxifylline , colonystimulating factor , interferon , interleukin within past 12 week . Known risk factor multidrug resistant ( MDR ) TB , include : Domicile , shelter , prison exposure know case MDR TB within past 6 month . Residence specific domicile , shelter , prison cell block within 6 month know outbreak MDR TB . Hospitalization , within past 6 month , medical service unit nosocomial transmission MDR TB know occur .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1995</verification_date>
	<keyword>Isoniazid</keyword>
	<keyword>Tuberculosis , Pulmonary</keyword>
	<keyword>Pyridoxine</keyword>
	<keyword>Ofloxacin</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Sputum</keyword>
	<keyword>Colony Count , Microbial</keyword>
</DOC>